Incannex is a clinical-stage pharmaceutical development company focused on discovering and developing life-changing medicines for patients struggling with serious, chronic diseases and limited treatment options. A leader in innovating proprietary cannabinoid pharmaceuticals and psychedelic-based therapies, we are developing medicines with the potential to alter the lives of patients suffering from obstructive sleep apnea (OSA), generalized anxiety disorder (GAD), and inflammatory disorders such as rheumatoid arthritis (RA). Working together in these relatively new fields with clinical, scientific, and drug development experts, we are efficiently innovating big solutions that are specifically designed and formulated to make a meaningful difference in patients’ lives. Founded in 2015 and headquartered in Melbourne, Australia, we are expanding in the U.S. and worldwide to help more patients and their families. Incannex trades on the Nasdaq Global Market under the symbol IXHL. 

Biotechnology

Cannabis

Health Care

Pharmaceutical

Therapeutics

Incannex Healthcare Inc

Incannex Healthcare Inc's headquarters in Melbourne, Australia

Joel Latham

Mark Bleackley

Lou Barbato

Lekhram Changoer

Joseph Swan

Incannex Healthcare Inc

Org chart

Teams

Offices

Similar companies